Endo Pharmaceuticals Earnings Conference Call (Q4 2007)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 22 Calls Today's Calls

Call Details Endo Pharmaceuticals Earnings Conference Call (Q4 2007) Fri, Feb 22, 2008, 11:00 am Eastern Listen to the archived event audio About Endo Pharmaceuticals (NasdaqGS:ENDP) Endo Pharmaceuticals Holdings, Inc. engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain. Its products include Lidoderm, a topical patch to relieve the pain of postherpetic neuralgia; Percocet and Percodan tablets; Frova tablets for the short-term prevention of menstrual migraine; Synera, a topical local anesthetic patch to provide local dermal anesthesia in children and adults; and Opana and Opana ER for the relief of moderate-to-severe pain in patients. The company’s generic products include Morphine Sulfate and Endocet, an oxycodone hydrochloride and acetaminophen product. Its products under development include Rapinyl, a phase III sub-lingual and fast-dissolving product for the treatment of breakthrough cancer pain; Topical Ketoprofen Patch, a phase III clinical trial product for the localized treatment of acute pain associated with soft-tissue injuries; LidoPAIN, a phase II clinical trial development lidocaine-based patch product for the treatment of acute lower back pain; and EN 3285 Oral Rinse, a clinical phase III product for the treatment for oral mucositis and other supportive care oncology conditions. The company is also developing Transdermal Sufentanil Patch, a phase IIa clinical product that provides relief from moderate-to-severe chronic pain for up to seven days; and CHRONOGESIC, an early stage clinical development product that treats patients with opioid responsive chronic pain. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, anesthesiology, oncology, and primary care. It has strategic alliances with Hind Healthcare for the development of Lidoderm; Penwest Pharmaceuticals Co. for Opana ER; and Vernalis Development Limited for Frova. The company was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings